natgillin/translations-raw huggingface dataset:
A peptide according to any one of claims 1 to 4, the cell according to claim 7, or the activated cytotoxic T lymphocyte according to claim 11 for use in the treatment of cancer. 
Peptid u skladu s bilo kojim od patentnih zahtjeva od 1 do 4, stanica u skladu sa zahtjevom 7 ili aktivirani citotoksični T-limfocit u skladu s patentnim zahtjevom 10 za upotrebu u liječenju karcinoma.
The compound of claim 1 wherein the compound has the formula: or the compound has the formula: 
[image] Spoj u skladu s patentnim zahtjevom 1, naznačen time, da spoj ima formulu:
The compound of claim 1 wherein the compound has the formula: or wherein 
Spoj u skladu s patentnim zahtjevom 1, naznačen time, da spoj ima formulu:
The compound of claim 1, wherein C1 is selected from the group consisting of phenyl, pyridyl, indolyl and thiazolyl, each of which is optionally substituted with from 1 to 3 R1 substituents; and wherein each R1 is independently selected from the group consisting of halogen, -CN, -Rc, -NRaRb and -ORa, and wherein each Ra and Rb is independently selected from hydrogen, C1-8 alkyl, and C1-8 haloalkyl, or when attached to the same nitrogen atom can be combined with the nitrogen atom to form a pyrrolidine ring; each Rc is independently selected from the group consisting of C1-8 alkyl, C1-8 haloalkyl and C3-6 cycloalkyl, and wherein the aliphatic and cyclic portions of Ra, Rb and Rc are optionally further substituted with from one to three hydroxy, methyl, amino, alkylamino and dialkylamino groups; and optionally when two R1 substituents are on adjacent atoms, are combined to form a fused five or six-membered carbocyclic ring. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je C1 odabran iz skupine koju čine fenil, piridil, indolil i tiazolil, od kojih je svaki prema potrebi supstituiran s od 1 do 3 supstituenta R1; i pri čemu je svaki R1 neovisno odabran iz skupine koja se sastoji od halogena, -CN, - Rc, -NRaRb i -ORa, i pri čemu je svaki Ra i Rb neovisno odabran iz skupine koju čine vodik, C1-8 alkil i C1-8 haloalkil, ili kada su vezani na isti atom dušika, mogu se kombinirati s dušikovim atomom i tvoriti pirolidinski prsten; svaki Rc neovisno je odabran iz skupine koja se sastoji od C1-8 alkila, C1-8 haloalkila i C3-6 cikloalkila, i pri čemu su alifatski i ciklički dijelovi Ra, Rb i Rc prema potrebi dodatno supstituirani s jednom do tri hidroksi, metil amino, alkilamino i dialkilamino skupine; i po želji, kada su dva supstituenta R1 na susjednim atomima, kombiniraju se tako da tvore peteročlani ili šesteročlani kaRbociklički prsten.
The compound of claim 7 wherein C1 is selected from the group consisting of 
Spoj u skladu s patentnim zahtjevom 7, naznačen time, da je C1 odabran iz skupine koju čine [image]
The compound of claim 1 wherein C3 is selected from the group consisting of: 
Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je C3 odabran iz skupine koju čine:
The compound of claim 1 wherein the compound is selected from the group consisting of: and 
Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je spoj odabran iz skupine koju čine:
A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound having the formula or a pharmaceutically acceptable salt, hydrate or rotomer thereof; wherein 
Farmaceutski pripravak, naznačen time, da sadržava farmaceutski prihvatljivi nosač i spoj formule [image] ili njegova farmaceutski prihvatljiva sol, hidrat ili rotomer; pri čemu
is selected from the group consisting of aryl and heteroaryl, wherein the heteroaryl group has from 1-3 heteroatoms as ring members selected from N, O and S; and wherein said aryl and heteroaryl groups are optionally substituted with from 1 to 3 R1 substituents; 
je odabran iz skupine koja se sastoji od arila i heteroarila, pri čemu heteroarilna skupina ima 1 do 3 heteroatoma u prstenu odabrana iz skupine koja se sastoji od N, O i S; i pri čemu su navedene aril i heteroaril skupine prema potrebi supstituirane sa 1 do 3 supstituenta R1;
A compound for use in a method of treating a mammal suffering from or susceptible to a disease or disorder involving pathologic activation of C5a receptors, wherein the disease or disorder is an inflammatory disease or disorder; a cardiovascular or cerebrovascular disorder; an autoimmune disorder; or a pathologic sequelae associated with the group consisting of insulin-dependent diabetes, mellitus, lupus nephropathy, Heyman nephritis, membranous nephritis, glomerulonephritis, contact sensitivity responses, and inflammation resulting from contact of blood with artificial surfaces; 
Spoj za uporabu u postupku liječenja sisavca koji pati od ili je sklon bolestima ili poRemećajima koji uključuju patološku aktivaciju C5a receptora, naznačen time, da je bolest ili poRemećaj upalna bolest ili poRemećaj; kardiovaskularni ili cerebrovaskularni poRemećaj; autoimuni poRemećaj; ili patološka posljedica povezane sa skupinom koju čine dijabetes ovisan o inzulinu, mellitus, lupus nefropatija, Heymann nefritis, membranski nefritis, glomerulonefritis, Reakcija na osjetljivost na kontakt i upala koje su posljedica kontakta krvi s umjetnim površinama;
is selected from the group consisting of aryl and heteroaryl, wherein the heteroaryl group has from 1-3 heteroatoms as ring members selected from N, O and S; and wherein said aryl and heteroaryl groups are optionally substituted with from 1 to 3 R2 substituents; 
je odabran iz skupine koja se sastoji od arila i heteroarila, pri čemu heteroarilna skupina ima 1 do 3 heteroatoma u prstenu odabrana iz skupine koja se sastoji od N, O i S; i pri čemu su navedene aril i heteroaril skupine prema potrebi supstituirane sa 1 do 3 R2 supstituenta;
the cardiovascular or cerebrovascular disorder is selected from the group consisting of myocardial infarction, coronary thrombosis, vascular occlusion, post-surgical vascular reocclusion, artherosclerosis, traumatic central nervous system injury and ischemic heart disease; and the autoimmune disorder is selected from the group consisting of rheumatoid arthritis, systemic lupus erythematosus, Guillain-Barre syndrome, pancreatitis, lupus nephritis, lupus glomerulonephritis, psoriasis, Crohn's disease, vasculitis, irritable bowel syndrome, dermatomyositis, multiple sclerosis, bronchial asthma, pemphigus, pemphigoid, scleroderma, myasthenia gravis, autoimmune hemolytic and thrombocytopenic states, Goodpasture's syndrome, immunovasculitis, tissue graft rejection and hyperacute rejection of transplanted organs. 
kaRdiovaskularni ili ceRebrovaskularni poRemećaj bira se iz skupine koju čine infarkt miokaRda, koronarna tromboza, vaskularna okluzija, postoperativna vaskularna Reokluzija, ateroskleroza, traumatska ozljeda sRedišnjeg živčanog sustava i ishemijske srčane bolesti; i autoimuni poRemećaj odabran je iz skupine koju čine Reumatoidni artritis, sistemski eritematozni lupus, Guillain-BarRe sindrom, pankReatitis, lupus nefritis, lupus glomerulonefritis, psorijaza, Crohnova bolest, vaskulitis, sindrom iritabilnog crijeva, dermatomiozitis, multipla skleroza, bronhijalna astma, pemfigus, pemfigoid, skleroderma, mijastenija gravis, autoimuna hemolitička i trombocitopenična stanja, GoodpastuReov sindrom, immunovasculitis, odbacivanje tkivnih transplantata i hiperakutno odbacivanja transplantiranih oRgana.
A compound for use according to claim 20 or 21, wherein the disease or disorder is an inflammatory disease or disorder. 
Spoj za uporabu u skladu s patentnim zahtjevom 20 ili 21, naznačen time, da je bolest ili poRemećaj upalna bolest ili poRemećaj.
A compound for use according to claim 20 or 21, wherein the disease or disorder is a cardiovascular or cerebrovascular disorder. 
Spoj za uporabu u skladu s patentnim zahtjevom 20 ili 21, naznačen time, da je bolest ili poRemećaj kaRdiovaskularni ili ceRebrovaskularni poRemećaj.
A compound for use according to claim 20 or 21, wherein the disease or disorder is an autoimmune disorder. 
Spoj za uporabu u skladu s patentnim zahtjevom 20 ili 21, naznačen time, da je bolest ili poRemećaj autoimuni poRemećaj.
A compound for use according to claim 20, wherein the disease or disorder is a pathologic sequelae associated with the group consisting of insulin-dependent diabetes, mellitus, lupus nephropathy, Heyman nephritis, membranous nephritis, glomerulonephritis, contact sensitivity responses, and inflammation resulting from contact of blood with artificial surfaces. 
Spoj za uporabu u skladu s patentnim zahtjevom 20, naznačen time, da je bolest ili poRemećaj patološka posljedica povezana sa skupinom koju čine dijabetes uvjetovan inzulinom, šećerna bolest, lupus nefropatija, Heymann nefritis, membranski nefritis, glomerulonefritis, Reakcija osjetljivosti na kontakt te upala uslijed kontakta krvi s umjetnim površinama.
comprising contacting mammalian white blood cells with a C5a receptor modulatory amount of the compound, which has the formula or is a pharmaceutically acceptable salt, hydrate or rotomer thereof; wherein 
naznačen time, da podrazumijeva dovođenje u kontakt bijelih krvnih stanica sisavaca s količinom spoja koja ima modulacijski učinak na Receptor C5a, a spoj ima formulu [image] ili je njegova farmaceutski prihvatljiva sol, hidrat ili rotomer istih; pri čemu
is selected from the group consisting of aryl and heteroaryl, wherein the heteroaryl group has from 1-3 heteroatoms as ring members selected from N, O and S; and wherein said aryl and heteroaryl groups are optionally substituted with from 1 to 3 R2 substituents; 
je odabran iz skupine koja se sastoji od arila i heteroarila, pri čemu heteroarilna skupina ima 1 do 3 heteroatoma u prstenu odabrana iz skupine koja se sastoji od N, i S i pri čemu su navedene aril i heteroaril skupine prema potrebi supstituirane sa do 3 supstituenta R2;
A method for the synthesis of γ,δ-dihydroxyisoleucine 1, or of a synthon for compound 1, comprising the step of methylating compound 3 with methyl iodide in the presence of lithium bis(trimethylsilyl)amide (LHMDS). 
Postupak sinteze γ,δ-dihidroksiizoleucina 1, ili sintona spoja 1, naznačen time, da obuhvaća korak metilacije spoja 3 ili 3* s metil jodidom u prisutnosti litij bis(trimetilsilil)amida (LHMDS). [image]
reaction of L-aspartic acid, monomethyl ester A with 2-methyl propene to create compound B; 
reakciju L-asparaginske kiseline, monometilni ester A s 2-metilpropenom, kako bi se dobio spoj B;
reaction of B with benzaldehyde to create compound C; 
reakciju B sa benzaldehidom kako bi se dobio spoj C;
oxidation of hydroxy compound D, particularly using a Swern oxidation, to create compound E; 
oksidacija hidroksi spoja D ili D*, naročito pomoću Swern oksidacije, kako bi se dobio spoj E odnosno spoj E*;
The method of any one of claims 1 to 4, further comprising the step of isolating and purifying compound 6, particularly wherein compound 6 is purified using precipitation as hydrochloride and/or chromatographic purification. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačen time, da postupak dodatno uključuje korak izoliranja i pročišćavanja spoja 6, osobito kada se spoj 6 pročišćava taloženjem hidroklorida i / ili kromatografskim pročišćavanjem.
The compound of claim 6, wherein the compound has a purity greater than 90%, particularly greater than 95%. 
Spoj u skladu s patentnim zahtjevom 6, naznačen time, da spoj ima čistoću veću od 90 %, naročito veću od 95 %.
The compound of claim 6, wherein the compound 6 a diastereomeric purity greater than 70: 30. 
Spoj u skladu s patentnim zahtjevom 6, naznačen time, da spoj 6 ima dijastereomernu čistoću veću od 70: 30.
A kit comprising compound 6, particularly comprising at least 100 mg of compound 6, and one or more additional reagents for the synthesis of amatoxins or precursors thereof. 
Komplet koji sadržava spoj 6, naznačen time, da osobito sadržava najmanje 100 mg spoja 6 i jedan ili više dodatnih reagensa za sintezu amatoksina ili njihovih prekursora.
a resin, particularly a resin selected from the group of: a Merrifield resin; a Rink-Amid resin; and a THP-resin; 
smola, osobito smola odabrana iz skupine koju čine Merrifieldova smola; Rink-amid smola i THP-smola;
A method for synthesizing an amatoxin, or precursor molecule therefor, comprising the step of (a) coupling compound 6 to hydroxyproline, particularly by reacting compound 6 with a hydroxyproline-preloaded resin, particularly by coupling compound 6 to the free C-terminus of FmocHypOH immobilized on a resin L, particularly a tetrahydropyranyl (THP) resin. 
Postupak sinteze amatoksina ili njegove prekursorske molekule, naznačen time, da obuhvaća korak: (a) spajanje spoja 6 s hidroksiprolinom, osobito reakcijom spoja 6 sa smolom prethodno napunjenom hidroksiprolinom, osobito vezanjem spoja 6 sa slobodnim C-krajem FmocHypOH imobiliziranog na smoli L, naročito tetrahidropiranil (THP) smoli. [image]
2-nitro aryl sulfonamide- N -deprotection and secession of I from resin to create compound J: 
[image] 2-nitro aril sulfonamid-N-deprotekcija i cijepanje od smole I kako bi se dobio spoj J:
The method of claim 11, wherein the amatoxin is an amatoxin with a dihydroxyisoleucine moiety as amino acid 3. 
Postupak u skladu s patentnim zahtjevom 11, naznačen time, da je amatoksin amatoksin s dihidroksiizoleucin skupinom kao aminokiselinom 3.
A method for the selection of bispecific single chain antibodies comprising a first binding domain capable of binding to an epitope of CD3 and a second binding domain capable of binding to the extracellular domain of prostate-specific membrane antigen (PSMA), comprising the steps of: 
Postupak odabira bispecifičnih jednolančanih protutijela, koja sadrže prvu vežuću domenu, koja se može vezati na epitop CD3, i drugu vežuću domenu, koja se može vezati na izvanstaničnu domenu membranskog antigena specifičnog za prostatu (PSMA), naznačen time što obuhvaća korake:
the wt human extracellular domain of PSMA having seq ID:447 on the cell surface; 
ljudsku izvanstaničnu domenu PSMA divljeg tipa sa SEQ ID:447 na površini stanice;
a mutated form of the wt human PSMA on the cell surface, wherein the amino acid residues at positions 140, 169, 191, 308, 334, 339, 344, 624, 626, 716, 717 and 721 are mutated to the corresponding amino acid residues of the wt rodent PSMA; and 
mutirani oblik ljudskog PSMA divljeg tipa na površini stanice, gdje su aminokiselinski ostaci na položajima 140, 169, 191, 308, 334, 339, 344, 624, 626, 716, 717 i 721 mutirani u odgovarajuće aminokiselinske ostatke PSMA glodavca divljeg tipa; i
the rodent wt extracellular domain of PSMA on the cell surface; 
izvanstaničnu domenu PSMA glodavca divljeg tipa na površini stanice;
A method for the selection of bispecific single chain antibodies comprising a first binding domain capable of binding to an epitope of CD3 and a second binding domain capable of binding to the extracellular domain of fibroblast activation protein a (FAPa), comprising the steps of: 
Postupak odabira bispecifičnih jednolančanih protutijela, koja sadrže prvu vežuću domenu, koja se može vezati na epitop CD3, i drugu vežuću domenu, koja se može vezati na izvanstaničnu domenu fibroblast-aktivirajućeg proteina a (FAPa), naznačen time što obuhvaća korake:
the wt human extracellular domain of FAPa having seq ID:448 on the cell surface; 
ljudsku izvanstaničnu domenu FAPa divljeg tipa sa SEQ ID:448 na površini stanice;
a mutated form of the wt human FAPa on the cell surface, wherein the amino acid residues at positions 144, 185, 186, 229, 267, 273, 274, 278, 284, 301, 328, 329, 331, 335 and 362 are mutated to the corresponding amino acid residues of the wt rodent FAPa; and 
mutirani oblik ljudskog FAPa divljeg tipa na površini stanice, gdje su aminokiselinski ostaci na položajima 144, 185, 186, 229, 267, 273, 274, 278, 284, 301, 328, 329, 331, 335 i 362 mutirani u odgovarajuće aminokiselinske ostatke FAPa glodavca divljeg tipa; i
the rodent wt extracellular domain of FAPa on the cell surface; 
izvanstaničnu domenu FAPa glodavca divljeg tipa na površini stanice;
A method for the selection of bispecific single chain antibodies comprising a first binding domain capable of binding to an epitope of CD3 and a second binding domain capable of binding to the extracellular domain of Hepatocyte Growth Factor Receptor (c-MET), endosialin (TEM1) and type 1 insulin-like growth factor receptor (IGF-1R), comprising the steps of: 
Postupak odabira bispecifičnih jednolančanih protutijela, koja sadrže prvu vežuću domenu, koja se može vezati na epitop CD3, i drugu vežuću domenu, koja se može vezati na izvanstaničnu domenu receptora čimbenika rasta hepatocita (c-MET), endosijalina (TEM1) i tip 1 receptora inzulinu sličnog čimbenika rasta (IGF-1R), naznačen time što se sastoji u koracima:
the human wt of the extracellular domain of the extracellular domain of c-MET, TEM1 or IGF-1R on the cell surface; 
ljudske izvanstanične domene divljeg tipa izvanstanične domene c-MET, TEM1 ili IGF-1R na površini stanice;
a fusion protein comprising the human membrane proximal 640 amino acid residues identified in step (a) and the rodent amino acid residues >640 of c-MET, TEM1 or IGF-1 R; and 
fuzijski protein koji sadrži ljudske membranske proksimalne 640 aminokiselinskih ostataka identificiranih u koraku (a) i glodavačke aminokiselinske ostatke >640 u c-MET, TEM1 ili IGF-1R; i
A bispecific single chain antibody comprising a first binding domain capable of binding to an epitope of CD3 epsilon (CD3ε) of human and non-chimpanzee primate, wherein the epitope is part of an amino acid sequence comprised in the group consisting of SEQ ID NOs. 
Bispecifično jednolančano protutijelo, naznačeno time što sadrži prva vežuća domena, koja se može vezati na epitop CD3 epsilon (CD3ε) kod čovjeka i primata koji nije čimpanza, gdje je epitop dio aminokiselinskog slijeda koji pripada skupini koju čine SEQ ID NO.
a binding domain capable of binding to the extracellular domain of the mutated human PSMA having an amino acid sequence as depicted in SEQ ID NO: 447, wherein the amino acid residues at positions 140, 169, 191, 308, 334, 339, 344, 624, 626, 716, 717 and 721 are mutated to the corresponding amino acid residues of the wt rodent PSMA, but not to the extracellular domain of the rodent PSMA; 
vežuća domena, koja se može vezati na izvanstaničnu domenu mutiranog ljudskog PSMA s aminokiselinskim slijedom kao što je opisan u SEQ ID NO: 447, gdje su aminokiselinski ostaci na položajima 140, 169, 191, 308, 334, 339, 344, 624, 626, 716, 717 i 721 mutirani u odgovarajuće aminokiselinske ostatke PSMA divljeg tipa glodavca, no ne i na izvanstaničnu domenu PSMA glodavca;
a binding domain capable of binding to the extracellular domain of the mutated human FAPa chimera having an amino acid sequence as depicted in SEQ ID NO: 448, wherein the amino acid residues at positions 144, 185, 186, 229, 267, 273, 274, 278, 284, 301, 328, 329, 331, 335 and 362 are mutated to the corresponding amino acid residues of the wt rodent FAPa, but not to the extracellular domain of the rodent FAPa; 
vežuća domena, koja se može vezati na izvanstaničnu domenu kimere mutiranog ljudskog FAPa s aminokiselinskim slijedom kao što je opisan u SEQ ID NO: 448, gdje su aminokiselinski ostaci na položajima 144, 185, 186, 229, 267, 273, 274, 278, 284, 301, 328, 329, 331, 335 i 362 mutirani u odgovarajuće aminokiselinske ostatke FAPa divljeg tipa glodavca, no ne i na izvanstaničnu domenu FAPa divljeg tipa;
A nucleic acid sequence encoding a bispecific single chain antibody molecule as defined in claim 8. 
Nukleinskokiselinski slijed, naznačen time što kodira molekulu bispecifičnog jednolančanog protutijela u skladu s patentnim zahtjevom 8.
A fusion protein comprising at least two amino acid sequences, wherein said two amino acid sequences consist of a first amino acid sequence having at least 90 % sequence identity with an amino acid sequence as shown in SEQ ID NO:2, fused to a second amino acid sequence having at least 90 % sequence identity with an amino acid sequence as shown in SEQ ID NO:4, wherein said fusion protein is capable of eliciting protective immunity against group B Streptococcus. 
Fuzijski protein sadrži najmanje dva slijeda aminokiselina, pri čemu se navedena dva slijeda aminokiselina sastoje od prvog slijeda aminokiselina koji ima najmanje 90% identičnosti slijeda sa slijedom aminokiselina prikazanim u SEQ ID NO:2, spojenim na drugi slijed aminokiselina koji ima najmanje 90% identičnosti slijeda sa slijedom aminokiselina prikazanim u SEQ ID NO:4, pri čemu je navedeni fuzijski protein sposoban potaknuti zaštitni imunitet prema Streptococcusu grupe B.
The fusion protein according to claim 3, wherein the fusion protein comprises an amino acid sequence having at least 95 % identity to the amino acid sequence shown in SEQ ID NO:6. 
Fuzijski protein u skladu s patentnim zahtjevom 3, pri čemu fuzijski protein obuhvaća slijed aminokiselina koji ima najmanje 95% identičnosti sa slijedom aminokiselina prikazanim u SEQ ID NO:6.
A vaccine comprising a pharmaceutically effective amount of a fusion protein according to any one of claims 1-5, wherein said vaccine composition is capable of eliciting protective immunity against group B Streptococcus comprising a pharmaceutically acceptable vehicle. 
Cjepivo koje sadrži farmaceutski učinkovitu količinu fuzijskog proteina u skladu s bilo kojim od patentnih zahtjeva 1-5, pri čemu navedeni sastav cjepiva sposoban potaknuti zaštitni imunitet prema Streptococcusu grupe B sadrži farmaceutski prihvatljivi nosač.
The vaccine according to claim 6, which further comprises an adjuvant. 
Cjepivo u skladu s patentnim zahtjevom 6, koje nadalje sadrži adjuvans.
A nucleotide sequence comprising at least the nucleotide sequence SEQ ID NO:1 coupled to SEQ ID NO:3 or the nucleotide sequence shown in SEQ ID NO:5. 
Slijed nukleotida koji obuhvaća najmanje slijed nukleotida SEQ ID NO:1 udružen sa SEQ ID NO:3 ili slijed nukleotida prikazan u SEQ ID NO:5.
The nucleotide sequence according to claim 9, wherein SEQ ID NO:1 and 3 are connected chemically, conjugated or cross-linked. 
Slijed nukleotida u skladu s patentnim zahtjevom 9, pri čemu su SEQ ID NO:1 i 3 kemijski povezani, konjugirani ili umreženi.
A vector comprising the nucleotide sequence according to claim 9-10. 
Vektor koji sadrži slijed nukleotida u skladu s patentnim zahtjevom 9-10.
treating intermediate of formula (3) with a base and subsequently with an acid in the presence of methanol; wherein 
obradu intermedijera s formulom (3) s bazom i nakon toga s kiselinom u prisutnosti metanola; [image] pri čemu
A method according to claim 1, wherein compound of formula (3) is obtained by reacting compound of formula (2) with nitromethane and a base. 
Postupak prema zahtjevu 1, naznačen time da je spoj s formulom (3) dobiven reakcijom spoja s formulom (2) s nitrometanom i bazom [image] .
is as defined above, 
je kako je definirano iznad,
A method according to claim 2 wherein the base employed for the conversion of compounds of formula (2) into compounds of formula (3) is DBU or TMG or derivatives thereof. 
Postupak prema zahtjevu 2 naznačen time da baza koja se koristi za pretvorbu spojeva s formulom (2) u spojeve s formulom (3) je DBU ili TMG ili njihovi derivati.
A method according to claim 10, wherein the simultaneous epimerization of compound of formula β-(4) to compound of formula a-(4) and the crystallization of compound of formula a-(4) is performed in methanol in the presence of an acid by evaporation or partial evaporation of the methanol. 
Postupak prema zahtjevu 10, naznačen time da se istovremena epimerizacija spoja s formulom β-(4) u spoj s formulom a-(4) i kristalizacija spoja s formulom a-(4) se provode u metanolu u prisutnosti kiseline isparavanjem ili djelomičnim isparavanjem metanola.
An intermediate having the formula a-(4). 
Intermedijer naznačen time da ima formulu a-(4).
An intermediate having the formula β-(4). 
Intermedijer naznačen time da ima formulu β-(4).